1. Dempke, WCM, Fenchel, K, Uciechowski, P, Dale, SP. Second- and third-generation drugs for immuno-oncology treatment: the more the better? Eur J Cancer. 2017 Mar;74:55–72.
Google Scholar | Crossref | Medline2. Alexander, J, Cukierman, E. Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions. Curr Opin Cell Biol. 2016 Oct;42:80–93.
Google Scholar3. Olive, KP, Jacobetz, MA, Davidson, CJ, Gopinathan, A, McIntyre, D, Honess, D, Madhu, B, Goldgraben, MA, Caldwell, ME, Allard, D, Frese, KK, Denicola, G, Feig, C, Combs, C, Winter, SP, Ireland-Zecchini, H, Reichelt, S, Howat, WJ, Chang, A, Dhara, M, Wang, L, Rückert, F, Grützmann, R, Pilarsky, C, Izeradjene, K, Hingorani, SR, Huang, P, Davies, SE, Plunkett, W, Egorin, M, Hruban, RH, Whitebread, N, McGovern, K, Adams, J, Iacobuzio-Donahue, C, Griffiths, J, Tuveson, DA. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009 Jun 12;324(5933):1457–61.
Google Scholar4. Koeppen, H, McCleland, M, Kowanetz, M. Predictive biomarkers and targeted therapies in immuno-oncology. In: Badve, S, Kumar, G, editors. Predictive biomarkers in oncology. Cham: Springer; 2019. p. 335–44.
Google Scholar5. Johnson, SK, Kerr, KM, Chapman, AD, Kennedy, MM, King, G, Cockburn, JS, Jeffrey, RR. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer. 2000 Jan;27(1):27–35.
Google Scholar6. Saxena, R. Dual immunohistochemistry—aniline blue stain: the trichrome stain revisited. J Histotechnology. 2010 Mar;33(1):25–9.
Google Scholar7. Hytiroglou, P, Tobias, H, Saxena, R, Abramidou, M, Papadimitriou, CS, Theise, ND. The canals of hering might represent a target of methotrexate hepatic toxicity. Am J Clin Pathol. 2004 Mar;121(3):324–9.
Google Scholar8. Mariathasan, S, Turley, SJ, Nickles, D, Castiglioni, A, Yuen, K, Wang, Y, Kadel, EE, Koeppen, H, Astarita, JL, Cubas, R, Jhunjhunwala, S, Banchereau, R, Yang, Y, Guan, Y, Chalouni, C, Ziai, J, Şenbabaoğlu, Y, Santoro, S, Sheinson, D, Hung, J, Giltnane, JM, Pierce, AA, Mesh, K, Lianoglou, S, Riegler, J, Carano, RAD, Eriksson, P, Höglund, M, Somarriba, L, Halligan, DL, van der Heijden, MS, Loriot, Y, Rosenberg, JE, Fong, L, Mellman, I, Chen, DS, Green, M, Derleth, C, Fine, GD, Hegde, PS, Bourgon, R, Powles, T. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018 Feb 22;554(7693):544–8.
Google Scholar9. Chen, DS, Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013 Jul;39(1):1–10.
Google Scholar | Crossref | Medline